Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This trial intends to enroll patients with T4N1 or T1-4N2-3 (AJCC 8th)
locoregionally-advanced nasopharyngeal carcinoma (LANPC). All the Patients will receive 3
cycles of induction chemotherapy with docetaxel and cisplatin and cisplatin based concurrent
chemoradiotherapy (CCRT) plus adjuvant immunotherapy (tisleilizumab). All patients will
receive intensity-modulated radiotherapy (IMRT). Tisleilizumab will begin 4-6 weeks after
CCRT and continue every 3 weeks for 12 cycles.
Phase:
Phase 2
Details
Lead Sponsor:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University